शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans

This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →

SHAILYNSEShaily Engineering Plastics Limited· Consumer DurablesCriticalPositive
Announced Tue, 19 May, 2026 · 17:58 IST

Shaily Engineering Plastics Limited has informed the Exchange regarding Outcome of Board Meeting held on May 19, 2026.

Profit growth above 25%EBITDA margin expansionResults View source PDFExplain this filing

SHAILY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+3.2%Reaction day
₹2630.00
prior close
₹2403.00
announcement price
After-mkt
timing
Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.6%+2.6% vs market
Plastic Products - Consumer peers, median of 7sector+1.4%+1.9% vs sector

On the reaction day the stock moved 2.6 pts more than Nifty Microcap 250 and 1.9 pts more than its Plastic Products - Consumer peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+3.4
10m
+5.4
15m
+13.4
30m
+12.4
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+3.2+0.6+2.6+1.4+1.9
Next day
+4.3+1.7+2.6+2.5+1.8
2d
+2.2+1.8+0.4+1.8+0.4
3d
+4.6+3.4+1.2+4.4+0.1
4d
+2.0+4.1-2.2+2.3-0.3
5d
+1.3+4.1-2.8+4.0-2.7
1w
+19.4+2.3+17.1+2.0+17.4
15d
+11.2+1.8+9.4+4.9+6.2
1m
+5.1+10.8-5.6+7.2-2.1
2m
+9.2+10.3-1.1+13.5-4.3
3m
+27.5+14.9+12.5+4.5+22.9
UpDownMarket · Nifty Microcap 250Sector · Plastic Products - Consumer peers, median of 7Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Shaily Engineering Plastics reported strong FY26 results with standalone revenue growing 21.5% to ₹921.2 crore and net profit more than doubling to ₹161.3 crore compared to FY25. Consolidated revenue rose 25.9% to ₹990.7 crore with net profit of ₹169.9 crore, up 82.5% year-on-year. The Board recommended a dividend of Rs. 3 per share (150%). The company also approved appointment of new internal and cost auditors, and appointed Mr. Chi Hung Kam as COO-Healthcare. Most significantly, an enabling resolution was passed for raising up to ₹500 crore to fund expansion into healthcare (drug delivery devices), consumer electronics, and semiconductor tray manufacturing through a new supply agreement with a Korean firm.

Likely market impact

Strong financial performance with over 20% revenue growth and 80%+ profit growth demonstrates solid execution. The ₹500 crore fund raise approval signals aggressive expansion plans into new high-growth segments like semiconductors and healthcare, which could significantly re-rate the stock if executed well.

By the numbersConsolidated · Q4 FY26 vs Q4 FY25
Q4 FY26Q4 FY25Change
Revenue₹236.8 Cr₹217.8 Cr+8.7%
Operating profit₹48.65 Cr₹39.47 Cr+23.2%
Profit after tax₹40.16 Cr₹28.59 Cr+40.5%
EBITDA margin27.7%25.0%+2.7 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.